Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer and UCB. The departures coincided with ...

Haleon was spun off from GSK amid investor pressure, showing steady growth but facing debt concerns. See more about HLN stock ...

Painkiller brands Panadol and Anadin will be bought under one roof under a giant deal between drug firms GlaxoSmithKline and Pfizer. The firms are combining their consumer healthcare businesses ...

GSK is the fifth company to leave BIO in roughly a year, a group that includes Pfizer (PFE). The departures coincided with a drop in lobbying spending from the group and other challenges, STAT says.

Haleon was formed in July 2019 through the merger of GlaxoSmithKline’s (GB:GSK) and Pfizer’s consumer healthcare businesses. Subsequently, in July 2022, GSK spun off Haleon as an independent ...

Pfizer is raising around $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon. The pharmaceutical giant is reducing its shareholding in Haleon to 22.6% from 32% ...

Pfizer and Mylan have announced an all-stock ... formed a joint venture for consumer health with GlaxoSmithKline, and agreed an $11.4 billion deal to acquire cancer specialist Array BioPharma.

Pfizer’s CEO Ian Read is resisting investor pressure to mastermind the next pharma mega-merger, saying that ... after bidders Reckitt Benckiser and GlaxoSmithKline pulled out.

Now, Novartis (Swiss) and GlaxoSmithKline (British ... about whether anything can really be a merger of equals - although while AstraZeneca may be the smaller company (its $87bn market cap is less ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...